These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 24884741)

  • 1. Tickling the TLR7 to cure viral hepatitis.
    Funk E; Kottilil S; Gilliam B; Talwani R
    J Transl Med; 2014 May; 12():129. PubMed ID: 24884741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of Memory B Cell Phenotypes and Toll-Like Receptor-7 in Chronic Hepatitis C Virus Infection During Direct-Acting Antiviral Interferon-Free Therapy: Correlation with Interleukin-7.
    Moustafa H; Madkour M; Hamed F; Abouelnazar S; Abo Elwafa R; Moaaz M
    Viral Immunol; 2021 May; 34(4):227-240. PubMed ID: 33180667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection.
    Rehermann B; Thimme R
    Gastroenterology; 2019 Jan; 156(2):369-383. PubMed ID: 30267712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B Gene Therapy Coming to Age.
    Soriano V
    AIDS Rev; 2018; 20(2):125-127. PubMed ID: 29938706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innate and adaptive immune responses in HCV infections.
    Heim MH; Thimme R
    J Hepatol; 2014 Nov; 61(1 Suppl):S14-25. PubMed ID: 25443342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
    Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
    J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B and C.
    Karnsakul W; Schwarz KB
    Pediatr Clin North Am; 2017 Jun; 64(3):641-658. PubMed ID: 28502443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of Toll-like receptor 7 expression in hepatitis-virus-related human hepatocellular carcinoma.
    Lin KJ; Lin TM; Wang CH; Liu HC; Lin YL; Eng HL
    Hum Pathol; 2013 Apr; 44(4):534-41. PubMed ID: 23069256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative review of HLA associations with hepatitis B and C viral infections across global populations.
    Singh R; Kaul R; Kaul A; Khan K
    World J Gastroenterol; 2007 Mar; 13(12):1770-87. PubMed ID: 17465466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toll-like receptor-mediated innate immunity orchestrates adaptive immune responses in HBV infection.
    Du Y; Wu J; Liu J; Zheng X; Yang D; Lu M
    Front Immunol; 2022; 13():965018. PubMed ID: 35967443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-hepatitis B virus (HBV) response of imiquimod based toll like receptor 7 ligand in hbv-positive human hepatocelluar carcinoma cell line.
    Das D; Sengupta I; Sarkar N; Pal A; Saha D; Bandopadhyay M; Das C; Narayan J; Singh SP; Chakrabarti S; Chakravarty R
    BMC Infect Dis; 2017 Jan; 17(1):76. PubMed ID: 28088184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
    Thomas A; Laxton C; Rodman J; Myangar N; Horscroft N; Parkinson T
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2969-78. PubMed ID: 17548497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis viruses and liver transplantation.
    Samuel D; Feray C; Bismuth H
    J Gastroenterol Hepatol; 1997 Oct; 12(9-10):S335-41. PubMed ID: 9407355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-Like Receptor 7 (TLR-7) and TLR-9 Agonists Improve Hepatitis C Virus Replication and Infectivity Inhibition by Plasmacytoid Dendritic Cells.
    Dominguez-Molina B; Machmach K; Perales C; Tarancon-Diez L; Gallego I; Sheldon JL; Leal M; Domingo E; Ruiz-Mateos E
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30232187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
    Wong GLH; Gane E; Lok ASF
    J Hepatol; 2022 Jun; 76(6):1249-1262. PubMed ID: 35589248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activating the innate immune response to counter chronic hepatitis B virus infection.
    Lamb C; Arbuthnot P
    Expert Opin Biol Ther; 2016 Dec; 16(12):1517-1527. PubMed ID: 27603796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A role for immune modulation in achieving functional cure for chronic hepatitis B among current changes in the landscape of new treatments.
    Laupèze B; Vassilev V; Badur S
    Expert Rev Gastroenterol Hepatol; 2023; 17(11):1135-1147. PubMed ID: 37847193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses.
    Ma Z; Zhang E; Yang D; Lu M
    Cell Mol Immunol; 2015 May; 12(3):273-82. PubMed ID: 25418467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral blood and hepatic Toll-like receptor 7 expression and interferon lambda 1 levels in chronic hepatitis C: Relation to virus replication and liver injury.
    El Aggan H; Farahat N; El Deeb N; Zeid A; El-Shendidi A
    Microb Pathog; 2019 Jun; 131():65-74. PubMed ID: 30926417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon.
    Mutz P; Metz P; Lempp FA; Bender S; Qu B; Schöneweis K; Seitz S; Tu T; Restuccia A; Frankish J; Dächert C; Schusser B; Koschny R; Polychronidis G; Schemmer P; Hoffmann K; Baumert TF; Binder M; Urban S; Bartenschlager R
    Gastroenterology; 2018 May; 154(6):1791-1804.e22. PubMed ID: 29410097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.